Report: US market for depression drugs to grow strongly through to 2025

Drug sales for major depressive disorders (MDD) in the US are expected to grow at a compound annual growth rate (CAGR) of 6.6% to reach $4.6bn by 2025, compared to $2.4bn in 2015, according to a report by GlobalData.

Source: Drug Development Technology - October 27, 2016 Category: Pharmaceuticals Source Type: news